Research
Molecular
BGM1812 was developed through a step-by-step modification process guided by structure-based drug design and molecular dynamics simulations.
Understanding the development process can inform future drug design strategies.
StrongSupportsmedium confidence
A step-by-step process involving three rounds of modifications was performed guided by structure-based drug design and molecular dynamics (MD) simulations.
Why this rating
The methodology described indicates a rigorous development process.
Source
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
Leilei Zong et al. · Journal of Medicinal Chemistry · 2025
otherCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →